Esperion Therapeutics Stock Today

ESPR Stock  USD 2.19  0.12  5.19%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 83

 
High
 
Low
Very High
Esperion Therapeutics is selling at 2.19 as of the 12th of April 2024; that is -5.19 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.19. Esperion Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Esperion Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of September 2022 and ending today, the 12th of April 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
26th of June 2013
Category
Healthcare
Classification
Health Care
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. The company has 185.05 M outstanding shares of which 19.92 M shares are currently shorted by private and institutional investors with about 4.07 trading days to cover. More on Esperion Therapeutics

Esperion Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Esperion Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Esperion Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO PresidentSheldon Koenig
Thematic IdeaDrugs (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Drugs, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Esperion Therapeutics report their recommendations after researching Esperion Therapeutics' financial statements, talking to executives and customers, or listening in on Esperion Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Esperion Therapeutics. The Esperion consensus assessment is calculated by taking the average forecast from all of the analysts covering Esperion Therapeutics.
Financial Strength
Based on the key indicators related to Esperion Therapeutics' liquidity, profitability, solvency, and operating efficiency, Esperion Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Esperion Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.540.5653
Sufficiently Down
Slightly volatile
Total Current Liabilities164 M156.2 M
Sufficiently Up
Slightly volatile
Total Assets181.9 M205.8 M
Fairly Down
Slightly volatile
Total Current Assets160.4 M201.1 M
Significantly Down
Slightly volatile
Esperion Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Esperion Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Esperion Therapeutics' bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Esperion Therapeutics' outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Esperion Therapeutics' financial leverage. It provides some insight into what part of Esperion Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Esperion Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Esperion Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Esperion Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 540.95 M in liabilities. Esperion Therapeutics has a current ratio of 3.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Esperion Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Esperion Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Esperion Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Esperion to invest in growth at high rates of return. When we think about Esperion Therapeutics' use of debt, we should always consider it together with cash and equity.

Other Non Cash Items

10.21 Million
Esperion Therapeutics (ESPR) is traded on NASDAQ Exchange in USA. It is located in 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108 and employs 240 people. Esperion Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 466.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Esperion Therapeutics's market, we take the total number of its shares issued and multiply it by Esperion Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Esperion Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 185.05 M outstanding shares of which 19.92 M shares are currently shorted by private and institutional investors with about 4.07 trading days to cover. Esperion Therapeutics currently holds about 185.84 M in cash with (135.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Esperion Therapeutics Probability Of Bankruptcy
Ownership Allocation
Esperion Therapeutics retains a total of 185.05 Million outstanding shares. 30% of Esperion Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Esperion Ownership Details

Esperion Stock Price Odds Analysis

In regard to a normal probability distribution, the odds of Esperion Therapeutics jumping above the current price in 90 days from now is about 81.76%. The Esperion Therapeutics probability density function shows the probability of Esperion Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Esperion Therapeutics has a beta of 0.6254 suggesting as returns on the market go up, Esperion Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Esperion Therapeutics will be expected to be much smaller as well. Additionally, esperion Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
  Odds Below 2.19HorizonTargetOdds Above 2.19
18.16%90 days
 2.19 
81.76%
Based on a normal probability distribution, the odds of Esperion Therapeutics to move above the current price in 90 days from now is about 81.76 (This Esperion Therapeutics probability density function shows the probability of Esperion Stock to fall within a particular range of prices over 90 days) .

Esperion Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Esperion Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Esperion Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Esperion Therapeutics' value.
InstituionRecorded OnShares
Two Sigma Advisers, Llc2023-12-31
2.1 M
Goldman Sachs Group Inc2023-12-31
2.1 M
Blackrock Inc2023-12-31
2.1 M
Jpmorgan Chase & Co2023-12-31
1.9 M
Tang Capital Management Llc2023-09-30
1.9 M
Parkman Healthcare Partners Llc2023-12-31
1.4 M
Renaissance Technologies Corp2023-12-31
1.4 M
Susquehanna International Group, Llp2023-12-31
1.4 M
Schonfeld Strategic Advisors Llc2023-09-30
1.2 M
Wasatch Advisors Inc.2023-12-31
8.9 M
Two Seas Capital Lp2023-12-31
7.7 M
View Esperion Therapeutics Diagnostics

Esperion Therapeutics Historical Income Statement

Esperion Therapeutics Income Statement is one of the three primary financial statements used for reporting Esperion's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Esperion Therapeutics revenue and expense. Esperion Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Esperion Therapeutics' Interest Expense is relatively stable compared to the past year. As of 04/12/2024, Other Operating Expenses is likely to grow to about 285.5 M, while Gross Profit is likely to drop slightly above 69.3 M. View More Fundamentals

Esperion Stock Against Markets

Picking the right benchmark for Esperion Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Esperion Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Esperion Therapeutics is critical whether you are bullish or bearish towards Esperion Therapeutics at a given time. Please also check how Esperion Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Esperion Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run ETF Categories Now

   

ETF Categories

List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
All  Next Launch Module

Esperion Therapeutics Corporate Directors

Esperion Therapeutics corporate directors refer to members of an Esperion Therapeutics board of directors. The board of directors generally takes responsibility for the Esperion Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Esperion Therapeutics' board members must vote for the resolution. The Esperion Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Tracy WoodyDirectorProfile
Dov GoldsteinIndependent DirectorProfile
Daniel JanneyIndependent DirectorProfile
Nicole VitulloDirectorProfile

How to buy Esperion Stock?

Before investing in Esperion Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Esperion Therapeutics. To buy Esperion Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Esperion Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Esperion Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Esperion Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Esperion Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Esperion Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Esperion Stock please use our How to Invest in Esperion Therapeutics guide.

Already Invested in Esperion Therapeutics?

The danger of trading Esperion Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Esperion Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Esperion Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Esperion Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Esperion Therapeutics is a strong investment it is important to analyze Esperion Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Esperion Therapeutics' future performance. For an informed investment choice regarding Esperion Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Esperion Stock analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Is Esperion Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Esperion Therapeutics. If investors know Esperion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Esperion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.03)
Revenue Per Share
1.128
Quarterly Revenue Growth
0.714
Return On Assets
(0.43)
Return On Equity
(2.61)
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Esperion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Esperion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Esperion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.